Literature DB >> 20676149

Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.

P A Thompson, H M Prince, J F Seymour, D Ritchie, K Stokes, K Burbury, M Wolf, S Peinert, T Joyce, S J Harrison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20676149     DOI： 10.1038/bmt.2010.180

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  4 in total

1.  A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.

Authors:  T-F Wang; M A Fiala; A F Cashen; G L Uy; C N Abboud; T Fletcher; N Wu; P Westervelt; J F DiPersio; K E Stockerl-Goldstein; R Vij
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

Review 2.  The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

Authors:  Robert Z Orlowski
Journal:  Oncology (Williston Park)       Date:  2011-11-15       Impact factor: 2.990

3.  Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.

Authors:  Yogesh S Jethava; Alan Mitchell; Joshua Epstein; Maurizio Zangari; Shmuel Yaccoby; Erming Tian; Sarah Waheed; Rashid Khan; Xenofon Papanikolaou; Monica Grazziutti; Michele Cottler-Fox; Nathan Petty; Douglas Steward; Susan Panozzo; Clyde Bailey; Antje Hoering; John Crowley; Jeffrey Sawyer; Gareth Morgan; Bart Barlogie; Frits van Rhee
Journal:  Clin Cancer Res       Date:  2016-11-03       Impact factor: 12.531

4.  Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.

Authors:  Toshihiro Miyamoto; Goichi Yoshimoto; Tomohiko Kamimura; Tsuyoshi Muta; Shuichiro Takashima; Yoshikiyo Ito; Motoaki Shiratsuchi; Ilseung Choi; Koji Kato; Katsuto Takenaka; Hiromi Iwasaki; Yasushi Takamatsu; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-07-23       Impact factor: 2.490
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.